Introduction
The cytochrome P-450 gene superfamily encodes for enzymes which catalyze oxidative biotransformations of hydrophobic endo and xenobiotics. Among the thirteen families described in man, four are involved in the detoxication of exogenous compounds, including drugs. Several cytochrome P450 loci are polymorphic in humans and contribute to genetically determined interindividual variation in drug response (Brosen, 1990 ; Nebert & Gonzalez, 1987) .
The debrisoquine-type polymorphism has been widely investigated (Brosen & Gram, 1990; Eichelbaum & Gross, 1990 ; Jacqz-Aigrain et Maghoub et al., 1977) using either debrisoquine as the probe drug or other drugs, such as dextromethorphan, sparteine and encainide. The reaction involves an enzymatic oxidation in the liver catalysed by a specific cytochrome P450 originally termed debrisoquine 4-hydroxylase (CYP2D).
Two metabolic phenotypes, extensive (EM) and poor (PM) metabolizers, were defined among Caucasian populations. PM have deficient oxidation, and account for 5 to 10% of the population (Alvan et al., 1990; Gonzalez & Meyer, 1991 PriceEvans etal., 1980; Sloan etal., 1983 Once the molecular DNA probes for CYP2D6 became available, several DNA nucleotide polymorphisms were described, especially those affecting the restriction sites (restriction fragment length polymorphism:RFLP). Three distinct patterns of XbaI RFLP (44kb, 11.5kb and 16 + 9kb) are associated with mutant alleles, while a 29kb XbaI fragment could represent either a normal (D6-wt) or a mutant allele (Dahl et al., 1992; Evans & Relling, 1990; Skoda et al., 1988) .
Molecular cloning identified the CYP2D locus as a cluster of three tandemly arranged genes. One (CYP2D6) codes for a functional protein, whereas the other two (CYP2D8 and CYP2D7), based on nucleotide sequence data, appear not to code for a cytochrome related protein (Kimura et al. 1989 ). The XbaI-defined 11.5kb allele corresponds to a deletion of the CYP2D6 gene , and the 44kb allele to a cluster with an additional gene (CYP2D7'). In this rearranged cluster the CYP2D6 gene carries a mutation, designated CYP2D6-B, at the splice site junction of intron 3 and exon 4 (Hanioka et al., 1990; Kagimoto et al., 1990) . A substantial percentage of XbaI 29kb mutated alleles also carry an identical mutation in the CYP2D6 gene. Clearly both the 11.5kb allele with the deletion of the functional gene and the 44kb allele with the CYP2D6-B mutation (44kbD6-B) cannot encode a functional protein, and hence must be poor metabolizer alleles. However, some cases in which the 44kb allele does not carry the D6-B mutation have been reported (Broly et al., 1991; Daly et al., 1990) .
A 44kb allele without the D6-B mutation could therefore either be functional, as recently reported by Dahl etal. (1992) Wolf et al., 1990) . Two polymorphic BamHl sites are located at an homologous position in the intervening sequence 1 of D7 and D6 genes, and the absence (-) or the presence (+) of these sites generates 6.6kb (-) or 4.9kb (+) fragments for D7 and 4.1kb (-) or 2.2kb (+) fragments for D6 (Kagimoto et al. 1990; Skoda et al., 1988 The molecular heterogeneity of this XbaI 44kb allele, was further examined by additional RFLP analyses with the BamHl restriction enzyme. Distinct polymorphic patterns were observed for the chromosomes with and those without the D6-B mutation. All 44kbD6-B alleles (with the D6-B mutation) were associated with the BamHl + + haplotype, including the two atypical haplotypes. The others (no D6-B mutation) were heterogenous, and were either BamHl --(n = 6), + + (n = 3) or-+ (n = 1) ( Table 1) . Three families were informative for determining the phenotype associated with the XbaI 44kb allele having no point mutations (D6-B and D6-A) or extra NcoI fragment (Figure 1.) . All of the members of the families were extensive metabolizers, as shown by their metabolic ratios. In family A, individual 12, an extensive metabolizer, is heterozygous for XbaI 44kb and 29kbD6-B, whereas IIl who is homozygous for XbaI 44kb is an extensive metabolizer. Thus, unambiguously the 44kb allele is associated with an extensive metabolizer allele, designated 44kb-em, in this family. Family B contains another example of the 44kb-em allele, although its combination with a XbaI 11.5kb allele (lack of functional CYP2D6 gene) results in an extensive metabolizer phenotype (individual 12). A third family (Family C) provides further evidence for the existence of another 44kb-em allele. Here, the D6-B mutation was assigned to the maternal XbaI 44kb fragment as this allele was associated with a NcoI 12.5kb fragment.
Families D and E, have genotypes comparable with family A and B, but the XbaI 44kb allele carries the D6-B mutation and is combined with known PM alleles. The 44kb allele in these two families is undoubtedly a PM allele, as indicated by the value of their log metabolic ratio.
We selected 47 subjects having comparable genotypes to determine whether the two previously defined XbaI 44kb haplotypes (XbaI 44kbD6-B and XbaI 44kbD6-em) correspond to two distinct phenotypic groups. Group I XbaI 44kbD6-B/29kbD6-wt contained 35 cases and group II XbaI 44kbD6-em/29kbD6-wt contained 12 cases. The mean urinary dextrorphan excretion over 8 h in group I was significantly lower than that in group II (P < 0.005) ( Table 2 ). However, the mean dextromethorphan excretion and metabolic ratios of the two groups were not statistically different owing to the low concentrations of unchanged drug.
Discussion
The advantage of DNA-based identification of poor and extensive metabolizer alleles over clinical phenotyping procedures is that it is free from interference from coadministered drugs or confounding diseases. It is also, in principle, a less invasive procedure as no probe drug administration is required to determine the phenotype, and is thus particularly suitable for pediatric and pregnant The heterogeneity of the XbaI-defined 44kb allele of the CYP2D locus with respect to phenotype has been noted, but not explored in detail (Broly etal., 1991; Daly et al., 1990) . The present results demonstrate the molecular heterogeneity of the XbaI-defined 44kb allele. The first level of heterogeneity is related to mutation in the functional gene. Although 75% of the 44kb alleles carry the D6-B mutation and represent the PM allele, 25% do not. This defines two groups of 44kb alleles:XbaI 44kbD6-B (group I) and XbaI 44kb-em (group II). The second level of heterogeneity is the associated polymorphisms for other restriction enzymes, such as NcoI and BamHl. The group I allele differs from that of group II in having an extra fragment in NcoI digests and a more intense regular D7-related BamHl fragment. The extra NcoI fragment (12.5kb or 4.8kb) in the XbaI 44kbD6-B haplotype strongly suggests the presence of an additional CYP2D6-related gene, probably D7', confirming published data (Hanioka et al., 1991 (Johanson et al., 1991) , is probably not true as the latter has an additional 12.5kb NcoI fragment, whereas XbaI 44kb-em (and hence 44E) does not. Our previous results demonstrate that these two alleles are distinct (Mura et al., 1991) . Alternatively, the 44-E allele and our XbaI44-em may be distinct, and hence not comparable as there is no NcoI data for the former. The group II alleles appear to be more heterogeneous with respect to the associated BamH1 polymorphism than the group I alleles, which all have the + + BamH1 pattern.
The homogeneous + + BamHl polymorphic pattern of group I alleles is of interest. Over 90% of the chromosomes bearing the D6-B mutation on a XbaI 29kb fragment also had a + + BamHl pattern (unpublished data). This tight linkage between BamH1 polymorphism and D6-B mutation suggests that XbaI-44D6-B might have been generated by a recombination event involving a mutant and a 29kbD6-wt allele.
Our genotype-phenotype data plus family information, indicate that ten of the forty-two 44kb alleles studied are extensive metabolizer alleles (44kbD6-em), so that individuals with a 44kb XbaI restriction fragment are not obligate extensive metabolizer heterozygotes. These 44kb-em alleles also lacked a 12.5kb or a 4.8kb NcoI fragment. Subjects with a 44kb allele may therefore be characterised by the combined information obtained by XbaI and NcoI RFLPs and PCR screening for D6-B. This is relevant and important, especially in epidemiological genotypic screening of individuals to predict the metabolic phenotype. They also explain some of the reported discrepancies in genotype-phenotype correlation (Broly et al., 1991; Daly et al., 1990; Turgeon et al., 1991) . However, it is intriguing to find that the presence of an additional gene coincides with the occurence of the D6-B mutation in the XbaI 44kbD6-B allele. Further data from different ethnic groups is necessary to understand this enigma.
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